AllNeuro Pathways Competitors

Lumosity is a leading brain training program, brought to you by Lumos Labs, Inc. Lumosity’s web and mobile games are designed by scientists to challenge core cognitive abilities. Lumosity’s scientists take neuropsychological and cognitive research tasks, or design new ones, and work with game designers to transform them into 50+ cognitive games. Designed to be both fun and adaptively challenging, Lumosity’s training program is accessible to people of all ages — helping them stay challenged to the full extent of their abilities. Lumos Labs also has a collaborative research initiative, the Human Cognition Project, which currently partners with over 90 university collaborators. Through the HCP, we grant qualified researchers free access to Lumosity’s cognitive training tasks, assessments, research tools, and, in some cases, limited access to data on cognitive task performance — helping them conduct larger, faster, and more efficient studies. For more information, please visit http://www.lumosity.com/hcp

Neurotrack is a cognitive care enablement platform that helps health systems, Medicare Advantage plans, ACOs, and value-based primary care groups find and diagnose cognitive impairment earlier. Dementia goes undiagnosed in primary care at alarming rates. Neurotrack gives care teams a practical way to change that at scale. Providers use our science-backed digital cognitive screening and assessment during routine care, including the Medicare Annual Wellness Visit (AWV), and patients can complete it in clinic or at home. Results are scored automatically and connect to a structured clinical pathway and patient-specific care plans through Smart Logic™, our proprietary clinical decision support engine. This helps primary care teams move from a positive screen to a confident dementia diagnosis and clear next steps. Neurotrack integrates with leading EHRs, including Epic and athenahealth, so results flow directly into the patient record and clinical workflow. We also support providers with CME courses and patient education resources. Neurotrack has published 27 peer-reviewed papers, holds 11 patents, and is registered as an FDA Class II medical device. Learn more at neurotrack.com.

BrainScope is a leading neurotechnology company advancing brain health through objective, AI-powered insights derived from brain electrical activity (EEG). Its proprietary platform analyzes EEG data from any source using advanced machine and deep learning to deliver rapid, radiation-free, accessible and cost-effective biomarkers - greatly expanding the clinical utility of traditional EEG. BrainScope's device for head injury assessment was the first device in neurology cleared by the FDA under the AI/Machine Learning-Enabled Medical Device category. BrainScope has commercialized its first set of FDA-cleared biomarkers for mild brain injury assessment (both brain bleeds and concussions) with remarkable outcomes in major U.S. health systems, which include ~50% reduction in unnecessary head CTs, substantial reductions in patient length of stay in emergency departments, and high utility for concussion clinics, personal injury cases and sports. The company is now advancing novel biomarkers for early Alzheimer’s detection, ARIA assessment, rapid stroke evaluation, concussion subtyping, military blast exposure, and others.